zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2011-8-2s-23zdor-1199Research ArticleБез разделаАЛЕМТУЗУМАБ В ЛЕЧЕНИИ БОЛЬНЫХС ХРОНИЧЕСКИМ ЛИМФОЛЕЙКОЗОМALEMTUZUMAB IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIAМорозоваО. М.MorozovaO. M.noemail@neicon.ru9-я городская клиническая больницаMunicipal Clinical Hospital № 920112812201102S6971Copyright © Морозова О.М., 20112011Морозова О.М.Morozova O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1199

В статье освещены результаты международных клинических исследований по использованию алемтузумаба у пациентов с хроническим лимфолейкозом, приведены результаты собственного применения алметузумаба как в монотерапии, так и в сочетании с химиопрепаратами (флюдарабином, циклофосфаном). Полученные результаты свидетельствуют о том, что применение алемтузумаба у больных с хроническим лимфолейкозом (ХЛЛ) является эффективным современным методом терапии.

The article elucidates the results of the international clinical research into the application of alemtuzumab in patients with chronic lymphatic leukemia (CLL) and presents the results of the application of alemtuzumab both in monotherapy and in the combination with chemomedicines (fludarabin, cyklofosfan). The received results testify that the application of alemtuzumab in CLL patients is an effective up-to-date method of therapy.

хронический лимфолейкозмоноклональные антителаалемтузумабchronic lymphatic leukemiahomogenious antibodiesalemtuzumabReferencesPhase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath- 1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) / J. Lundin // Blood. - 2002. - Vol. 100 (3). - P. 768-773.Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath- 1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) / J. Lundin // Blood. - 2002. - Vol. 100 (3). - P. 768-773.Therapeutic role of alemtuzumab (Campath-1H) in patient, who have failed fludarabine: results of a large international study / M. J. Keating // Blood. - 2002. - Vol. 99. - P. 3554-3561.Therapeutic role of alemtuzumab (Campath-1H) in patient, who have failed fludarabine: results of a large international study / M. J. Keating // Blood. - 2002. - Vol. 99. - P. 3554-3561.Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival / P. Moreton [et al.] // J. Clin. Oncol. - 2005. - Vol. 23. - P. 2971-2979.Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival / P. Moreton [et al.] // J. Clin. Oncol. - 2005. - Vol. 23. - P. 2971-2979.Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia / B. Kennedy [et al.] // Blood. - 2002. - Vol. 99. - P. 2245-2247.Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia / B. Kennedy [et al.] // Blood. - 2002. - Vol. 99. - P. 2245-2247.

The authors declare that there are no conflicts of interest present.